Diablo Clinical Research

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Obesity6 trials
• Type 1 diabetes6 trials
• Type 2 diabetes6 trials
• Migraine2 trials
• Coronary artery disease1 trial

Phase

• Phase 39 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 21 trial

Status

• Recruiting6 trials
• Completed5 trials
• Active, not recruiting3 trials
• Suspended1 trial
• Withdrawn1 trial

Lead sponsor

• Amgen5 trials
• Boehringer Ingelheim3 trials
• Medtronic MiniMed, Inc.2 trials
• TriGemX Bio, Inc.2 trials
• COUR Pharmaceutical Development Company, Inc.1 trial
• and 3 more

Running trials

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  NCT07684235· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM

  NCT07296276· i-SENS, Inc.· Source

  Contact: Principal Investigator, MD

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

  NCT06783309· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

  Contact: Drew Jaffe

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Amgen· Source

• Active, not recruiting

  Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus

  NCT06627517· Luna Diabetes· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Migraine2 recruiting
• Type 1 diabetes2 recruiting
• Coronary artery disease1 recruiting
• Obesity1 recruiting

Closed trials

• Withdrawn

  SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

  NCT06719531· Medtronic MiniMed, Inc.· Source

• Completed

  Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

  NCT06272695· Phase 1· REMD Biotherapeutics, Inc.· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM

  NCT05714059· Medtronic MiniMed, Inc.· Source

• Completed

  Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  NCT05669599· Phase 2· Amgen· Source